Opendata, web and dolomites

GlyCan

Innovative Glycan-based analysis for Cancer diagnostics

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 GlyCan project word cloud

Explore the words cloud of the GlyCan project. It provides you a very rough idea of what is the project "GlyCan" about.

tkac    kit    diagnostics    advisors    prior    biopsies    patients    74    blood    dr    innovative    economic    competitive    2nd    healthy    quantify    combined    launched    competitors    suspicious    glycan    positive    pain    rate    invasive    diagnostic    dna    homes    commercial    members    pca    discriminates    representing    sick    home    business    covered    digital    erc    protein    worldwide    psa    clinics    biopsy    glycanostics    mrna    ing    check    quantifying    annually    outcome    proteins    epo    centres    jan    cancer    confirm    deaths    b2b    team    false    screening    mistreatment    consists    company    dre    instead    6m    lacks    opinion    detect    serum    simplicity    owned    undergo    grant    market    accurately    biomarker    granted    b2c    366k    needless    patent    75    burden    95    clinically    core    antigen    hospital    biomarkers    rectal    circulating    advantage    sending    biomolecules    scientific    dx    examinations    societal    examination    311532    cso    assay    co    prostate    founder    preliminary    accuracy    throughput   

Project "GlyCan" data sheet

The following table provides information about the project.

Coordinator
GLYCANOSTICS SRO 

Organization address
address: DUBRAVSKA CESTA 9
city: BRATISLAVA
postcode: 845 38
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Slovakia [SK]
 Project website https://www.glycanostics.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-02-01   to  2019-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GLYCANOSTICS SRO SK (BRATISLAVA) coordinator 50˙000.00

Map

 Project objective

Worldwide, there are 1.6M new prostate cancer (PCa) cases with 366k deaths annually. Novel PCa biomarkers are needed since the best current PCa biomarker (prostate specific antigen (PSA)) lacks PCa diagnostic accuracy often resulting in mistreatment of PCa patients. The false-positive rate of PSA in blood serum is ~75%. PSA test is applied together with digital rectal examination (DRE) for preliminary screening. If the combined results are suspicious, the patients undergo a biopsy to confirm PCa. Yet, there are 74% of needless biopsies representing a significant pain for PCa patients and societal/economic burden.

Based on a great commercial outcome from the ERC grant (311532) granted to Dr. Jan Tkac (co-founder/CSO of Glycanostics), the company has developed an innovative, non-invasive, early PCa diagnostics using blood serum. Instead of quantifying PSA, the innovative PCa diagnostic assay detect glycan changes on PSA protein (it discriminates between “healthy” PSA and “sick” PSA and accurately quantify the clinically relevant “sick” PSA). The technology is covered by two EPO patent applications owned by the company. The PCa diagnostic test with 95% accuracy will be applied as a 2nd opinion test in case of suspicious results from PSA & DRE examinations prior sending to a biopsy. PCa DX kit will be launched for clinics/hospital & cancer centres (B2B) and Prostate check home test for user-friendly application at homes (B2C).

Our PCa diagnostic technology is unique compared to our competitors focusing on analysis of other complex biomolecules such as a level of proteins, mRNA and circulating DNA. Moreover, we have competitive advantage over competitors in terms of cost per sample, assay accuracy, simplicity of the assay enabling the home testing and high-throughput.

Glycanostics consists of 7 core team members, 4 business and 4 scientific advisors making a great and highly experienced team that will bring these innovative PCa early diagnostic products to the market.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GLYCAN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GLYCAN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Savesight (2020)

Contact lens embedded sensor for ocular hypertension and glaucoma monitoring

Read More  

Proteus 25 (2018)

Developing the world’s first food wrapping machine with organic film

Read More  

Preemie (2019)

Personalised nutrition of low-birth-weight infants

Read More